Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001385 · ClinicalTrials.gov registry record
Positron Emission Tomography in Patients With Breast Cancer
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 75
- Enrollment target
NCT00001385: Completed study, sponsored by National Cancer Institute (NCI).
NCT00001385 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001385 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 75 participants
- Enrollment target
Study Summary
This is a prospective study evaluating the role of Positron Emission Tomography (PET scan) in breast cancer. The radiopharmaceutical \[18F\] 2-deoxyglucose will be used as both an imaging modality and to evaluate tumor metabolism in patients with breast cancer. Patients with stage II, stage IIIA or IIIB, or stage IV breast cancer and evaluable disease in the breast and/or at metastatic sites will be studied. Patients will be injected intravenously with \[18F\]2-deoxyglucose and a PET scan conducted over 90 minutes. Examination of the role of PET scan in assessing the response of breast cancer to chemotherapy, especially in stage II and stage III patients, will be done. Up to three PET scans within one year may be performed. Findings by PET scan will be correlated both with those of concurrent imaging techniques (x-ray, CT scan, MRI, bone scan or mammogram), and with histologic, biochemical, and flow cytometric information on the tumor, and with findings in subsequent surgical specimens. Changes in tumor glucose metabolism with treatment will be assessed by PET imaging studies and by biochemical methods when possible.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 1994-05 |
| Est. Completion | 2000-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001385
The ClinicalTrials.gov registry entry for NCT00001385 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00001385 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00001385 about?
NCT00001385 is a clinical study titled "Positron Emission Tomography in Patients With Breast Cancer". This is a prospective study evaluating the role of Positron Emission Tomography (PET scan) in breast cancer. The radiopharmaceutical \[18F\] 2-deoxyglucose will be used as both an imaging modality and to evaluate tumor metabolism in patients with breast cancer. Patients with stage II, stage IIIA or ...
What is the current status of trial NCT00001385?
This trial is currently completed. The enrollment target is 75 participants. The study started on 1994-05. Estimated completion is 2000-04.
Who is sponsoring clinical trial NCT00001385?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.